Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Keravis, Thérèse ^a   Monneaux, Fanny ^b   Yougbaré, Issaka ^a   Gazi, Lucien ^a,c   Bourguignon, Jean Jacques ^a   Muller, Sylviane ^b   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 FLUOROBENZYL) 6 N METHYL 2 TRIFLUOROMETHYLADENINE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DENBUFYLLINE; PENTOXIFYLLINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG; 2 TRIFLUOROMETHYL 9 (2 FLUOROPHENYLMETHYL) N METHYLADENINE; 2-TRIFLUOROMETHYL-9-(2-FLUOROPHENYLMETHYL)-N-METHYLADENINE; ADENINE; CYCLIC AMP; DRUG DERIVATIVE; ISOENZYME; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DISEASE COURSE; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; IC 50; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PROTEINURIA; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CBA MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; HUMAN; KIDNEY; METABOLISM; MORTALITY; SECRETION;

MUS;

ADENINE; ANIMALS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE PROGRESSION; FEMALE; HUMANS; ISOENZYMES; KIDNEY; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED CBA; MICE, INBRED MRL LPR; PENTOXIFYLLINE; PHOSPHODIESTERASE 4 INHIBITORS; PROTEINURIA; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; XANTHINES;

EID: 84855676055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028899     Document Type: Article

References (45)

1. Johnson AE, Gordon C, Palmer RG, Bacon PA, (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38: 551-558.
2. Rahman A, Isenberg DA, (2008) Systemic lupus erythematosus. N Engl J Med 358: 929-939.
3. Monneaux F, Muller S, (2009) Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Therapy 11: 234.
4. Lugnier C, (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
5. Tenor H, Schudt C, (1996) Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In: Schudt C, Dent G, Klaus Rabe KF, editors. Phoshodiesterase inhibitors pp. 21-40 The Handbook of Immunopharmacology, Clive Page, series Ed.
6. Jin SL, Conti M, (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99: 7628-7633.
7. Jin SL, Lan L, Zoudilova M, Conti M, (2005) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175: 1523-1531.
8. Nandi JS, Nair KG, Deo S, (1980) Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline-a new xanthine derivative. Adv Myocardiol 1: 359-365.
9. Wilke R, Arch JR, Nicholson CD, (1989) Tissue selective inhibition of cyclic nucleotide phosphodiesterase by denbufylline. Arzneimittelforschung 39: 665-667.
10. Komas N, Lugnier C, Stoclet JC, (1991) Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104: 495-503.
11. Bourguignon JJ, Désaubry L, Raboisson P, Wermuth CG, Lugnier C, (1997) 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors. J Med Chem 40: 1768-1770.
12. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S, (2003) T cell recognition and therapeutic effects of a phosphorylated synthetic peptide of the 70 K snRNP protein administered in MRL/lpr lupus mice. Eur J Immunol 33: 287-296.
13. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, et al. (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273: 1396-1402.
14. Souness JE, Rao S, (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9: 227-236.
15. Houslay MD, Schafer P, Zhang KY, (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
16. Houslay MD, Adams DR, (2010) Putting the lid on phosphodiesterase 4. Nat Biotechnol 28: 38-40.
17. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, et al. (2002) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052.
18. Ahloulay M, Bankir L, Lugnier C, Le Bec A, Poirel O, et al. (2005) Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites. Liver Int 25: 403-409.
19. Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, et al. (2008) Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 58: 3873-3883.
20. Houslay MD, (2010) Underpinning compartmentalized cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100.
21. Conti M, Beavo J, (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
22. Wang H, Peng MS, Chen Y, Geng J, Robinson H, et al. (2007) Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 408: 193-201.
23. Hecht M, Müller M, Lohmann-Matthes ML, Emmendörffer A, (1995) In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 57: 242-249.
24. Segal R, Dayan M, Zinger H, Mozes E, (2001) Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus 10: 23-31.
25. Muller B, Lugnier C, Stoclet JC, (1990) Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J Cardiovasc Pharmacol 16: 796-803.
26. Reimund JM, Raboisson P, Pinna G, Lugnier C, Bourguignon JJ, et al. (2001) Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4-inhibiting properties. Biochem Biophys Res Commun 288: 427-434.
27. Boichot E, Wallace JL, Germain N, Corbel M, Lugnier C, et al. (2000) Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. J Pharmacol Exp Ther 292: 647-653.
28. Barreto EO, Carvalho VF, Lagente V, Lugnier C, Cordeiro RS, et al. (2004) Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol 4: 755-762.
29. Yougbaré I, Morin CS, Senouvo FY, Sirois C, Albadine R, et al. (2011) NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol 301: L441-L450.
30. Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C, et al. (2008) Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol 154: 82-92.
31. Mori F, Pérez-Torres S, De Caro R, Porzionato A, Macchi V, et al. (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40: 36-42.
32. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, et al. (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28: 63-70.
33. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, et al. (2010) The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-56.
34. Bruno O, Fedele E, Prickaerts J, Parker L, Canepa E, et al. (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol doi: 10.1111/j.1476-5381.2011.01524.
35. Souness JE, Rao S, (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 19: 227-236.
36. Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, et al. (2007) Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol 573: 93-99.
37. Keravis T, Thaseldar-Roumié R, Lugnier C, (2005) Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol 307: 63-74.
38. Follénius A, Gérard D, (1984) Fluorescence investigations of calmodulin hydrophobic sites. Biochem Biophys Res Commun 119: 1154-1160.
39. Lugnier C, Bruch M, Stoclet JC, Strub MP, Marivet M, et al. (1985) Substituted carbostyrils as inhibitors of cyclic AMP phosphodiesterase. Eur J Med Chem 20: 121-125.
40. Marivet MC, Bourguignon JJ, Lugnier C, Mann A, Stoclet JC, et al. (1989) Inhibition of cyclic-adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem 32: 1450-1457.
41. Richter W, Jin SL, Conti M, (2005) Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 388: 803-811.
42. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
43. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC, (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743-1751.
44. Kameni-Tcheudji JF, Lebeau L, Virmaux N, Maftei CG, Cote RH, et al. (2001) Molecular organization of bovine rod cGMP-phosphodiesterase 6. J Mol Biol 310: 781-791.
45. Schneider HH, Schmiechen R, Brezninski M, Seidler J, (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127: 105-115.